pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·1h ago·1 min read
save

AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal

Nov 19, 2026·read at BioSpace ↗

There’s a party going on at DISCO Pharma’s European headquarters after the precision medicine biotech signed its second major pharma partnership of the year—first Amgen, now AbbVie.

source

Reporting by BioSpace.

read at BioSpace ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h ago9 biotechs will cut at least half their California workforcesBioSpace
  • 3h agoRamping up: 3 biotechs growing their workforce after series C raisesBioSpace
  • 15h agoCTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questionsBioSpace
  • 16h agoCTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBioSpace
  • 17h agoMerck scraps centerpiece of $2.7B ArQule buy after late-stage safety concernsBioSpace